Navigation Links
Pitt-Stanford research suggests aimless proteins crucial to disease
Date:3/31/2011

PITTSBURGHResearchers from the University of Pittsburgh and Stanford University discovered that a supposedly inactive protein actually plays a crucial role in the ability of one the world's most prolific pathogens to cause disease, findings that suggest the possible role of similarly errant proteins in other diseases.

The team reports in the Proceedings of the National Academy of Sciences (PNAS) that Toxoplasma gondiithe parasitic protozoa behind toxoplasmosisattacks healthy cells by first injecting them with pseudokinases, which are enzymes that have abandoned their original function of transferring phosphates. When the researchers engineered strains of T. gondii without a particular pseudokinase gene cluster called ROP5, the pathogen was subsequently unable to cause disease in micea notable loss of potency in an organism that can infect nearly any warm-blooded animal.

These results are among the first to implicate pseudokinases as indispensible actors in pathogen-based disease, said senior author Jon Boyle, a professor in the Department of Biological Sciences in Pitt's School of Arts and Sciences. Boyle coauthored the paper with John Boothroyd, a professor of microbiology and immunology in the Stanford School of Medicine. Boyle and Boothroyd worked with Michael Reese, a postdoctoral researcher in Boothroyd's lab, as well as Gusti Zeiner and Jeroen Saeij, former postdoctoral researchers under Boothroyd.

The Pitt-Stanford project suggests that the significance of these aimless enzymes to T. gondii could apply to pseudokinases in other pathogens, Boyle said, including the parasite's close relative Plasmodium, which causes malaria.

"Our work shows that just because these proteins have lost their original function does not mean they don't do anything," Boyle said. "T. gondii cannot cause disease without them, and if one is trying to understand how pathogens work, the role of these proteins should obviously be considered."

The ROP5, or rhoptry protein 5, gene clusterso named for the specialized organelle rhoptry, which secretes thembelongs to a larger family of approximately 40 pseudokinases present in T. gondii. Once T. gondii injects ROP5 into the host cell, the parasite enters the cell and forms a protective membrane pocket, or vacuole, around itself to which ROP5 and other proteins attach. While the other secreted kinases are known to help disable or disrupt activity in the host cell, the ROP5 cluster, a kind of infectious ringleader, appeared to have a more dominant role in causing severe disease in mice than other virulence factors, Boyle said.

The team plans to further investigate the significance of ROP5 to T. gondii's survival within the host, Boyle said. In the PNAS paper, the researchers suggest that ROP5 has undergone multiple rounds of gene duplication followed by mutation of the individual copies. Thus, the authors propose, the ROP5 cluster may act like a genetic Swiss Army Knife, a multipurpose tool that allows T. gondii to adapt to and infect its famously wide variety of hosts.


'/>"/>

Contact: Morgan Kelly
mekelly@pitt.edu
412-897-1400
University of Pittsburgh
Source:Eurekalert

Related medicine news :

1. New strategic plan for NIH obesity research seeks to curb epidemic
2. Researchers need to engage lesbian, gay, bisexual, and transginder populations in health studies
3. Researchers publish molecular disease model for melanoma
4. Researchers find possible clues to tamoxifen resistance in breast cancer patients
5. UCSF researchers identify promising new treatment for childhood leukemia
6. Research explores link between asthma and smoking
7. Researchers make the leap to whole-cell simulations
8. UT Southwestern research advances fight against kidney cancer
9. Stepchildren relate to stepparents based on perceived benefits, researchers find
10. Researchers find many elderly men are undergoing unnecessary PSA screenings
11. LGBT health research gaps and needs: IOM report release March 31
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2017)... ... 26, 2017 , ... IndustryArchive.Org . is announcing a new way for ... will now only pay for B.A.N.T. quality sales leads based on the Sellers decision ... the new reality that B2B buyers are controlling the sales process via the Internet ...
(Date:2/26/2017)... Miami, Florida (PRWEB) , ... February 26, 2017 ... ... disease (PD) patients after receiving cognitive rehabilitation, according to a study released today ... already known that cognitive rehabilitation programs are proven to be effective in improving ...
(Date:2/24/2017)... ... February 24, 2017 , ... HealthPostures, ... Go. Core benefits and advantages built into the home office sit stand solution ... and feel. Ability to gain the benefits embedded in the TaskMate Go are ...
(Date:2/24/2017)... ... 24, 2017 , ... WHAT: , The New Jersey Tech ... well as advocacy for the state and region‘s technology businesses, hosted their 2017 ... Council's Innovation Forecast event highlights innovation throughout the region from small to large ...
(Date:2/24/2017)... ... February 24, 2017 , ... The Smart Machine Age is here, and ... that 47 percent of all jobs in the United States may be taken over ... day of the aggressive know-it-all who steamrolls over colleagues is drawing to a close. ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... ITL Limited, ( ASX : ITD ), une société de ... excellents résultats semestriels clos le 31 décembre 2016 par ... « Résultats et mise à jour sur la croissance biomédicale ... Faits marquants Bénéfice ... hausse de 104 %) Bénéfice par action ...
(Date:2/24/2017)... 2017 Non-alcoholic steatohepataitis (NASH) Pipeline ... drugs being developed for the treatment of ... that are in various phases of development ... on novel pharmacologic drugs & regenerative medicines ... recombinant proteins and RNA-based therapeutics, but excludes ...
(Date:2/24/2017)... Wyoming , Feb. 24, 2017  Xynomic Pharmaceuticals, ... today announced that it has acquired exclusive worldwide ... potentially best-in-class innovative HDAC inhibitor targeting hematological and ... of 14 Phase 1 and 2 clinical trials ... Asia have already been completed, demonstrating ...
Breaking Medicine Technology: